LON:IMM ImmuPharma Final Earnings Report GBX 4.33 -0.10 (-2.26%) As of 12:25 PM Eastern ProfileEarnings History ImmuPharma EPS ResultsActual EPS-GBX 0.37Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AImmuPharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmuPharma Announcement DetailsQuarterFinalDate5/27/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile ImmuPharma Earnings HeadlinesImmuPharma (LON:IMM) Stock Crosses Below 200 Day Moving Average - Here's What HappenedJune 4 at 3:37 AM | americanbankingnews.comImmuPharma focused on securing P140 licensing deal in 2026May 28, 2026 | uk.finance.yahoo.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.June 5 at 1:00 AM | Profits Run (Ad)ImmuPharma launches regulatory push for Kapiglucagon diabetes drugMay 6, 2026 | uk.finance.yahoo.comImmuPharma PLCApril 24, 2026 | marketwatch.comImmuPharma: P140 partnering discussions continue; overwhelming backing for investment roundApril 9, 2026 | uk.finance.yahoo.comSee More ImmuPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuPharma and other key companies, straight to your email. Email Address About ImmuPharmaImmuPharma (LON:IMM) (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.View ImmuPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Lulu of a Miss Sends Lululemon to New Lows—Look Out BelowFive Below Down 12% Post Earnings—Is the Selloff Overdone?Buy the Dip? Broadcom's AI Moat Is Wider Than EverThe Market Has Ollie’s Bargain Outlet Completely WrongBroadcom's Whiplash: Shares Tank After Pre-Earnings SurgeMacy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains CautiousThe Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
